一项了解艾曲莫德对溃疡性结肠炎患者疗效的研究 (EFFECT-UC)
艾曲莫德对溃疡性结肠炎疾病活动性和患者报告结果的有效性 - EFFECT-UC
The purpose of this real world non-interventional study is to learn about the effects of etrasimod as treatment for patients with moderate to severe ulcerative colitis.
Patients will be treated according to standard of care and will only be included in the study if etrasimod is the best treatment choice according to the treating physician. Additionally, patients have to be between 18 and 65 years of age and should not have taken etrasimod in the past.
All patients will be prescribed etrasimod according to standard of care. Assessments will be conducted according to standard of care with the exception of health questionnaires which will be completed by the patients online on their own device.
The study duration is 52 weeks with 28 days of safety follow-up. Patients will visit their treating physician as they would if they were not enrolled in the study. During the study duration, patients will be asked to complete health questionnaires on a regular basis either on their mobile phone, tablet or computer.
The effects of etrasimod will be analyzed for each patient comparing to their disease activity prior to the start of etrasimod.
研究概览
研究类型
注册 (估计的)
联系人和位置
学习地点
-
-
British Columbia
-
Kelowna、British Columbia、加拿大、V1Y 6J6
- Kelowna Gastroenterology Associates
-
New Westminster、British Columbia、加拿大、V3L 3E3
- Columbia Medical Building
-
Richmond、British Columbia、加拿大、V7C 5L9
- Richmond Hospital
-
Vancouver、British Columbia、加拿大、V5Z 1M9
- Vancouver Coastal Health
-
Vancouver、British Columbia、加拿大、V6Z 2K5
- Providence Health Care (PHC)
-
-
Ontario
-
London、Ontario、加拿大、N6A5A5
- London Health Sciences Centre
-
Ottawa、Ontario、加拿大、K1H8L6
- Ottawa Hospital
-
-
Quebec
-
Montreal、Quebec、加拿大、H3G 1A4
- Montreal General Hospital
-
Montreal、Quebec、加拿大、H2X 3E4
- CHUM
-
Montreal、Quebec、加拿大、H4J 1C4
- Hôpital du Sacré-Cœur de Montréal
-
-
-
-
-
Aachen、德国、52064
- MVZ Gastroenterologie Aachen
-
Andernach、德国、56626
- Praxis Heil und Müller
-
Berlin、德国、10825
- MVZ für Gastroenterologie am Bayerischen Platz
-
Cologne、德国、51103
- Evangelisches Krankenhaus Kalk
-
Dachau、德国、85221
- MVZ Dachau
-
Frankfurt am Main、德国、60594
- Interdisziplinares Crohn Colitis Centrum
-
Grevenbroich、德国、41515
- Facharztpraxis für Gastroenterologie
-
Halle、德国、06108
- Studiengesellschaft BSF UG.
-
Heidelberg、德国、69115
- Praxis für Gasteroenterologie
-
Lübeck、德国、23560
- Praxis für Gasteroenterologie Lübeck
-
Lüneburg、德国、21339
- Klinikum Lüneburg
-
Oldenburg、德国、10115
- Internistische Praxengemeinschaft Oldenburg
-
Remscheid、德国、42859
- Magen-Darm-Zentrum Remscheid
-
Wesseling、德国、50389
- CED am Rhein
-
-
Breisgau
-
Freiburg im Breisgau、Breisgau、德国、79102
- Gastrofreiburg
-
-
Hesse
-
Kassel、Hesse、德国、34117
- Gastroenterologie OpernstraBe
-
-
-
-
-
Crumpsall、英国、M8 5RB
- Northern Care Alliance NHS Foundation Trust, Greater Manchester
-
Kent、英国、TN2 4QJ
- Tunbridge Wells Hospital
-
London、英国、SE59RS
- Kings College Hospital
-
London、英国、NW1 2PG
- University College London Hospital
-
London、英国、E1 1BB
- Barts Health NHS Trust, The Royal London Hospital
-
London、英国、HA1 3UJ
- St. Mark's Hospital
-
London、英国、SE1 7EH
- St Thomas' Hospital - Guy's & St Thomas' NHS Foundation Trust
-
London、英国、SW17 0QT
- St George's Hospital - St George's Healthcare Nhs Trust
-
London、英国、W2 1PG
- Imperial College Healthcare NHS
-
Newport、英国、NP20 2UB
- Royal Gwent Hospital
-
Southampton、英国、SO16 6YD
- Southampton University Hospitals NHS Trust
-
-
Lanarkshire
-
Glasgow、Lanarkshire、英国、G4 0SF
- NHS Greater Glasgow and Clyde
-
-
Nottinghamshire
-
Nottingham、Nottinghamshire、英国、NG7 2UH
- Nottingham University Hospitals NHS Trust, Queens Medical Centre
-
-
Oxfordshire
-
Oxford、Oxfordshire、英国、OX3 9DU
- Oxford University Hospitals NHS Foundation Trust
-
-
Scotland
-
Edinburgh、Scotland、英国、EH4 2XU
- Western General Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Eligible patients can be included in this study if their physician makes a clinical decision to treat them with etrasimod, as defined by the local approved label and independent from the decision to enroll the patient in this study.
描述
Inclusion Criteria:
- Male and female patients ≥18 and <65 years of age at baseline
- Patients with confirmed diagnosis of ulcerative colitis and who are prescribed etrasimod for moderately to severely active ulcerative colitis as per the product label independently of the decision to enroll a patient in this study.
- Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.
Exclusion Criteria:
-
Presence of clinical findings suggestive of Crohn's disease.
-
Severe extensive colitis evidenced by:
-
Physician judgement that the patient is likely to require hospitalization for medical or surgical intervention of any kind for UC (eg, colectomy) within 12 weeks.
-
Current evidence of acute severe UC, fulminant colitis, or toxic megacolon 3. Patients with a stoma or planned UC surgical intervention requiring hospitalization.
4. Prior/Concomitant Therapy:
- any previous exposure to etrasimod including participation in the etrasimod clinical program.
- any co-medication with one of the following conventional therapies: methotrexate or a thiopurine (azathioprine, mercaptopurine or tioguanine) or with any of the following advanced therapies for UC: biologics (a TNF, integrin or cytokine antagonist); JAK inhibitors (filgotinib, tofacitinib or upadacitinib) or with any other S1P receptor modulator.
-
-
Not owning a digital device with internet connection and/or not willing to complete health questionnaires on this device or not capable of using the health questionnaire collection tool.
-
Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
接受艾曲莫德治疗溃疡性结肠炎的患者
|
As provided in real world practice |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of patients with symptomatic remission
大体时间:Week 12
|
Symptomatic remission was defined as stool frequency sub score (SFS)= 0 (or = 1 with a ≥ 1-point decrease from baseline) and rectal bleeding sub score (RBS) =0.. Stool frequency score and rectal bleeding score are components of the Patient-Reported Outcome-2 score derived based on components of Mayo score (PRO2): instrument designed to measure disease activity of ulcerative colitis. Total score range: stool frequency 0 to 3 and rectal bleeding 0 to 3; higher score=more severe disease. |
Week 12
|
|
Proportion of patients with symptomatic remission
大体时间:Week 52
|
Symptomatic remission was defined as stool frequency sub score (SFS)= 0 (or = 1 with a ≥ 1-point decrease from baseline) and rectal bleeding sub score (RBS) =0.. Stool frequency score and rectal bleeding score are components of the Patient-Reported Outcome-2 score derived based on components of Mayo score (PRO2): instrument designed to measure disease activity of ulcerative colitis. Total score range: stool frequency 0 to 3 and rectal bleeding 0 to 3; higher score=more severe disease. |
Week 52
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of patients with clinical response
大体时间:Week 12
|
Clinical response was defined as decrease of at least 20% in Patient-Reported Outcome-2 score derived based on components of Mayo score (PRO2) from baseline or achievement of symptomatic remission. |
Week 12
|
|
Proportion of patients with clinical response.
大体时间:Week 52
|
Clinical response was defined as decrease of at least 20% in Patient-Reported Outcome-2 score derived based on components of Mayo score (PRO2) from baseline or achievement of symptomatic remission. |
Week 52
|
|
Proportion of corticosteroid-free patients with symptomatic remission
大体时间:Week 52
|
Symptomatic remission was defined as stool frequency sub score (SFS)= 0 (or = 1 with a ≥ 1-point decrease from baseline) and rectal bleeding sub score (RBS) =0.. Stool frequency score and rectal bleeding score are components of the Patient-Reported Outcome-2 score derived based on components of Mayo score (PRO2): instrument designed to measure disease activity of ulcerative colitis. Total score range: stool frequency 0 to 3 and rectal bleeding 0 to 3; higher score=more severe disease. Patients have to be corticosteroid-free for at least 12 weeks prior to the visit. |
Week 52
|
合作者和调查者
赞助
调查人员
- 研究主任:Pfizer CT.gov Call Center、Pfizer
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- C5041041
- EFFECT-UC (其他标识符:Alias Study Number)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.